GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Wuxi AppTec Co Ltd (SHSE:603259) » Definitions » EBIT

Wuxi AppTec Co (SHSE:603259) EBIT : ¥11,574 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Wuxi AppTec Co EBIT?

Wuxi AppTec Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥2,348 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥11,574 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Wuxi AppTec Co's annualized ROC % for the quarter that ended in Mar. 2024 was 13.20%. Wuxi AppTec Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 31.90%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Wuxi AppTec Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 9.51%.


Wuxi AppTec Co EBIT Historical Data

The historical data trend for Wuxi AppTec Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuxi AppTec Co EBIT Chart

Wuxi AppTec Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,419.31 3,511.20 6,083.72 10,725.97 11,885.60

Wuxi AppTec Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,660.04 3,808.62 3,427.26 1,989.68 2,348.47

Competitive Comparison of Wuxi AppTec Co's EBIT

For the Diagnostics & Research subindustry, Wuxi AppTec Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuxi AppTec Co's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Wuxi AppTec Co's EV-to-EBIT falls into.



Wuxi AppTec Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥11,574 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuxi AppTec Co  (SHSE:603259) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Wuxi AppTec Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=7976.204 * ( 1 - 14.74% )/( (51557.322 + 51451.639)/ 2 )
=6800.5115304/51504.4805
=13.20 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=73669.349 - 8336.965 - ( 13775.062 - max(0, 14756.296 - 30422.471+13775.062))
=51557.322

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=74939.848 - 7259.565 - ( 16228.644 - max(0, 13387.433 - 31153.382+16228.644))
=51451.639

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Wuxi AppTec Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=9393.892/( ( (25563.522 + max(4430.443, 0)) + (25641.507 + max(3252.718, 0)) )/ 2 )
=9393.892/( ( 29993.965 + 28894.225 )/ 2 )
=9393.892/29444.095
=31.90 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(7901.38 + 4736.23 + 2587.032) - (8336.965 + 0 + 2457.234)
=4430.443

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6968.835 + 5047.974 + 1451.442) - (7259.565 + 0 + 2955.968)
=3252.718

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Wuxi AppTec Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=11574.033/121695.718
=9.51 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuxi AppTec Co EBIT Related Terms

Thank you for viewing the detailed overview of Wuxi AppTec Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuxi AppTec Co (SHSE:603259) Business Description

Traded in Other Exchanges
Address
288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, CHN, 200131
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services through the discovery, development, and manufacturing spectrum for small-molecule drugs, cell therapies, and gene therapies as well as providing testing services for medical devices. Its segments comprise China-based laboratory services; U.S.-based laboratory services; Clinical research and other CRO services; CDMO services; and Others. The majority of revenue gets derived from China-based laboratory services that include small molecules discovery, such as synthetic chemistry, medicinal chemistry, analytical chemistry, biology, drug metabolism and pharmacokinetics (DMPK)/absorption, distribution, metabolism, and excretion (ADME), toxicology and bioanalytical services.

Wuxi AppTec Co (SHSE:603259) Headlines

No Headlines